Pipeline

Cerenis is developing a broad pipeline of HDL therapies to address the needs of a variety of patients in both the sub-acute and chronic care cardiovascular disease (CVD) markets.

For severe atherosclerosis patients, Cerenis is developing intravenous (IV) infusion products designed to rapidly regress atherosclerotic plaque. For patients with dyslipidemia and low HDL, Cerenis is developing oral therapies for enhancement of HDL function. In both categories, the goal is to dramatically reduce cardiovascular morbidity and mortality beyond what is possible with current therapies.